Skip to main content

Table 1 Event risk setting

From: Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINA® Trial

Event risk Values
Event risk of SoC (event number/PY) HR for linagliptin plus SoC (95% CI)
Nonfatal myocardial infarction 19/608.1 0.87 (0.45, 1.69)
Nonfatal stroke 10/610.9 0.60 (0.22, 1.66)
Hospitalisation for unstable angina 3/614.3 0.68 (0.11, 4.07)
Hospitalisation for heart failure 23/596.3 0.47 (0.24, 0.95)
Albuminuria progression 63/245.7 0.95 (0.66, 1.36)
Renal failure 14/612.5 0.58 (0.24, 1.39)
CV death 13/622.5 0.70 (0.30, 1.64)
  1. CI confidence interval, CV cardiovascular, HR hazard ratio, PY person-year, SoC standard of care